Mepivacaine


Amide local anesthetic (intermediate-acting)

The methyl-substituted pipecoloxylidide parent of bupivacaine and ropivacaine, used in dental and orthopedic regional anesthesia.

Abstract

Mepivacaine (1-methyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; CAS 96-88-8; molecular formula C15H22N2O; molecular weight 246.35) is an amide local anesthetic synthesized by Bo af Ekenstam at AB Bofors in the same pipecoloxylidide series that produced bupivacaine and ropivacaine. The compound was introduced clinically in the late 1950s (Carbocaine, Polocaine) as a successor to lidocaine for dental and short-procedure regional anesthesia. The methyl substituent on the piperidine nitrogen makes mepivacaine the shortest-acting member of the pipecoloxylidide family; lipid solubility and protein binding are intermediate between lidocaine and bupivacaine. Mechanism is voltage-gated sodium channel block. Onset is 3 to 5 minutes for infiltration; duration is 2 to 3 hours, longer with epinephrine. The principal niches in current practice are dental anesthesia (the 3 percent plain solution avoids epinephrine in patients where the vasoconstrictor is contraindicated, and the intermediate duration matches typical dental procedure length), and ambulatory orthopedic spinal anesthesia where the shorter duration relative to bupivacaine permits earlier ambulation and discharge. Mepivacaine is sold as a racemate. Cardiotoxicity is intermediate between lidocaine and bupivacaine; lipid emulsion rescue applies to LAST. The ester-class procaine and chloroprocaine are alternative short-acting infiltration agents; mepivacaine retains a market niche owing to the absence of the para-aminobenzoic acid metabolite that drives ester allergic reactions.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph